\(\)




gliclazide
glibenclamidegliclazide30%glipizede


metformin1.5
peroxisome proliferative-activated receptor-γ
(PPAR-γ)

glitazone(Thiazolidinedione)
(hepatotoxicity)
ALT
(
lactasesucrase)
1. Inzucchi SE : Oral antihyperlgycemic therapy for type 2 diabetes.
JAMA 287:360-372, 2002.
2. Luna, B, feinglos MNOral agets in the management of type 2
diabetes mellitus. Am Fam physician 63:1747-1756, 2001.
4 -1-P.- 4 -
*NA=
4-2
Repaglinide 1+ 1+ 0 0 0 0
Metformin 0 - 0 2+ 1+ 0
Acarbose 0 0 0 3+ 0 +
Rosiglitazone 0 3+ 2 0 0 0*
Pioglitazone 0 3+ 2 0 0 0*
* ALT, AST
- =; 0 = ; + =; 1+ =; 2+ =; 3+ =; 4+ = ;
4 -1-P.- 6 -
66%38%UKPDS
15
C-peptide



4 -2-P- 7 -

Lente 1-2 4-8 10-20

()
2/31/3
25 kg/m 2 0.6-1.0
NPH insulinregular insulin
2/3 NPH1/3 regular
insulinNPH insulinregular insulin1/2

Endocrinol Metab Clin North Am 2001, 30:909-933.
2. Carlton FB: Recent advances in the pharmacologic management of
diabetes mellitus. Emergency Medicine Clin North Am 2000,
18:745-753.
insulin(Neutral Protamine Hagedon)/30%RI (Regular Insulin)
50%NPHI/50%RI75%NPH insulin/25%lispro
U-10U-40U-100U-500(1040100
500 36)U-10
U-500
(
insulin NPH insulin
(5812.5)(U-40
U-100U-500)



( pen-like device and
insulin-containing cartridges )
()





4 -2-P20
4 -2-P21